The advent of Sodium Glucose Transporter 2-inhibitors (SGLT2-i) in recent years gave endocrinologists the opportunity to actively treat and prevent heart failure (HF) in patients with type 2 diabetes (T2DM). While the relationship between T2DM and HF has been extensively reviewed, previous works focused mostly on epidemiology, pathophysiology and treatment of HF in T2DM. The aim of our work was to aid health care professionals in identifying individuals at high risk for this dreadful complication. Recent guidelines recommend to use drugs with proven cardiovascular benefits (Glucagon-like peptide-1 receptor agonists (GLP1-RA) and SGLT2-i) in patients with previous cardiovascular disease (CVD) and to prefer SGLT2-i in patients with known HF. In everyday clinical practice, the choice between these two drug classes in patients without known HF or atherosclerotic CVD is mostly arbitrary and based on the side effect profile. Recently, risk stratification tools to estimate HF incidence have been developed in order to guide treatment with a view to bring precision medicine into diabetes care. With this purpose, we provide a review of the tools able to predict HF incidence for patients in primary CVD prevention as well as risk of future hospitalizations for patients with known HF.

Cannistraci, R., Mazzetti, S., Mortara, A., Perseghin, G., & Ciardullo, S. (2020). Risk stratification tools for heart failure in the diabetes clinic. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 30(7), 1070-1079 [10.1016/j.numecd.2020.03.022].

Risk stratification tools for heart failure in the diabetes clinic

Cannistraci R.
Primo
;
Perseghin G.
;
Ciardullo S.
Ultimo
2020

Abstract

The advent of Sodium Glucose Transporter 2-inhibitors (SGLT2-i) in recent years gave endocrinologists the opportunity to actively treat and prevent heart failure (HF) in patients with type 2 diabetes (T2DM). While the relationship between T2DM and HF has been extensively reviewed, previous works focused mostly on epidemiology, pathophysiology and treatment of HF in T2DM. The aim of our work was to aid health care professionals in identifying individuals at high risk for this dreadful complication. Recent guidelines recommend to use drugs with proven cardiovascular benefits (Glucagon-like peptide-1 receptor agonists (GLP1-RA) and SGLT2-i) in patients with previous cardiovascular disease (CVD) and to prefer SGLT2-i in patients with known HF. In everyday clinical practice, the choice between these two drug classes in patients without known HF or atherosclerotic CVD is mostly arbitrary and based on the side effect profile. Recently, risk stratification tools to estimate HF incidence have been developed in order to guide treatment with a view to bring precision medicine into diabetes care. With this purpose, we provide a review of the tools able to predict HF incidence for patients in primary CVD prevention as well as risk of future hospitalizations for patients with known HF.
Articolo in rivista - Review Essay
Scientifica
diabetes; heart failure; risk stratification
English
Cannistraci, R., Mazzetti, S., Mortara, A., Perseghin, G., & Ciardullo, S. (2020). Risk stratification tools for heart failure in the diabetes clinic. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 30(7), 1070-1079 [10.1016/j.numecd.2020.03.022].
Cannistraci, R; Mazzetti, S; Mortara, A; Perseghin, G; Ciardullo, S
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/277340
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
Social impact